ArticleClinical genitourinary cancer2023

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.

Emerson A Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.